<DOC>
	<DOCNO>NCT00004224</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining one drug combine chemotherapy radiation therapy may kill tumor cell . PURPOSE : This phase II trial study combination chemotherapy radiation therapy see well work treat child localize ependymoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Radiation Therapy Treating Children With Localized Ependymoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine event free overall survival child incompletely resect localized ependymoma treat adjuvant cyclophosphamide , etoposide , vincristine follow radiotherapy . - Determine response rate patient regimen . OUTLINE : This multicenter study . Patients undergo surgery remove much tumor possible . Patients residual disease proceed chemotherapy , residual disease proceed directly radiotherapy . Chemotherapy begin within 3 week surgery consist vincristine IV day 1 , 8 , 15 , cyclophosphamide IV 3 hour day 1 , etoposide IV 4 hour day 1-3 . Treatment repeat every 4 week 4 course . Patients progress 2 course proceed radiotherapy . If residual disease still present completion chemotherapy , second look surgery recommend . Patients undergo radiotherapy daily 6 week begin complete resection within 4 week surgery , within 3 week completion chemotherapy , within 4 week second look surgery . Patients follow 6 week radiotherapy , every 2 month 1 year , every 4 month 2 year , every 6 month 2 year , annually 5 year . PROJECTED ACCRUAL : A total 65 patient accrue study within 2-3 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven nonmetastatic intracranial ependymoma Cellular Papillary Clear cell Mixed cell Anaplastic No myxopapillary ependymoma , subependymoma , ependymoblastoma PATIENT CHARACTERISTICS : Age : 3 20 Performance status : Not specify Life expectancy : Not specify Hematopoietic : No hematologic disease would preclude study participation Hepatic : Not specify Renal : No renal disease would preclude study participation Other : No concurrent unrelated disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior steroid allow Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>childhood infratentorial ependymoma</keyword>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
</DOC>